GlassScriptPhysician profile
Roland J Chan
NPI 1912986100
$6,318.74
in general payments reported to CMS, 2019-2025
21 companies · $1,456 in 2025
The $1,456 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $237 · 2020: $549 · 2021: $785 · 2022: $849 · 2023: $627 · 2024: $1,816 · 2025: $1,456.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,729 · Education: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,728.74 |
| Education | $169.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,542.03 | 2019-2025 | Rinvoq, Skyrizi |
| Amgen INC. | $1,443.99 | 2019-2025 | Enbrel, Otezla, Tavneos |
| Janssen Biotech, INC. | $501.22 | 2021-2025 | Tremfya |
| Lilly USA, LLC | $358.29 | 2019-2023 | Taltz |
| E.R. Squibb & Sons, L.L.C. | $215.27 | 2020-2025 | Orencia |
| Ucb, INC. | $203.40 | 2023-2025 | Bimzelx, Cimzia |
| Astrazeneca Pharmaceuticals LP | $168.38 | 2021-2025 | Saphnelo |
| Horizon Therapeutics Plc | $153.52 | 2019-2022 | |
| Genzyme Corporation | $152.79 | 2024 | |
| Hikma Pharmaceuticals USA | $135.84 | 2020-2021 | |
| Glaxosmithkline, LLC. | $121.74 | 2021-2025 | Benlysta |
| Fresenius Kabi USA, LLC | $51.63 | 2024 | Idacio |
| Alexion Pharmaceuticals, INC. | $48.81 | 2021-2022 | |
| Sobi, INC | $44.24 | 2024-2025 | |
| Pfizer INC. | $34.91 | 2022-2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $32.80 | 2025 | Opsynvi |
| Regeneron Healthcare Solutions, INC. | $25.47 | 2019 | |
| Scilex Pharmaceuticals INC. | $24.85 | 2024 | |
| Sandoz INC. | $22.17 | 2024 | Hyrimoz |
| Novartis Pharmaceuticals Corporation | $18.89 | 2019 | |
| Tonix Medicines, INC. | $18.50 | 2025 | Tonmya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roland Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.